

# Juanjuan Xiang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1779056/publications.pdf>

Version: 2024-02-01

34  
papers

1,387  
citations

430874

18  
h-index

395702

33  
g-index

36  
all docs

36  
docs citations

36  
times ranked

2227  
citing authors

#	ARTICLE	IF	CITATIONS
1	Construction of PARPi Resistance-related Competing Endogenous RNA Network. <i>Current Genomics</i> , 2022, 23, 262-274.	1.6	1
2	Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance. <i>Nature Communications</i> , 2022, 13, .	12.8	21
3	EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF- $\beta$ <sup>2</sup> /SMAD signalling. <i>British Journal of Cancer</i> , 2021, 124, 1301-1311.	6.4	31
4	Systematic Investigation of DNA Methylation Associated With Platinum Chemotherapy Resistance Across 13 Cancer Types. <i>Frontiers in Pharmacology</i> , 2021, 12, 616529.	3.5	4
5	Lung microbiome alterations in NSCLC patients. <i>Scientific Reports</i> , 2021, 11, 11736.	3.3	25
6	Proteomic profiling of extracellular vesicles and particles reveals the cellular response to cisplatin in <sc>NSCLC</sc>. <i>Thoracic Cancer</i> , 2021, 12, 2601-2610.	1.9	8
7	Chromatin accessibility regulates chemotherapy-induced dormancy and reactivation. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 269-279.	5.1	15
8	Genome instability and lymphoma. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 552-557.	0.1	0
9	BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment. <i>Cancer Biology and Therapy</i> , 2020, 21, 61-71.	3.4	11
10	Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development. <i>Frontiers in Oncology</i> , 2020, 10, 531131.	2.8	7
11	Ligand-independent EphB1 signaling mediates TGF- $\beta$ <sup>2</sup> -activated CDH2 and promotes lung cancer cell invasion and migration. <i>Journal of Cancer</i> , 2020, 11, 4123-4131.	2.5	19
12	Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. <i>Microbiome</i> , 2020, 8, 74.	11.1	67
13	VPS41-BRAF, a novel BRAF fusion gene identified in a lung adenocarcinoma patient by next-generation sequencing. <i>Lung Cancer</i> , 2020, 146, 380-381.	2.0	1
14	Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. <i>Molecular Cancer</i> , 2019, 18, 40.	19.2	350
15	Cancer-educated mesenchymal stem cells promote the survival of cancer cells at primary and distant metastatic sites via the expansion of bone marrow-derived-PMN-MDSCs. <i>Cell Death and Disease</i> , 2019, 10, 941.	6.3	45
16	Remodeling the Microenvironment before Occurrence and Metastasis of Cancer. <i>International Journal of Biological Sciences</i> , 2019, 15, 105-113.	6.4	15
17	Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis. <i>Oncogene</i> , 2019, 38, 3061-3076.	5.9	69
18	miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas. <i>BMC Cancer</i> , 2018, 18, 1293.	2.6	13

#	ARTICLE	IF	CITATIONS
19	Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5776-5786.	3.6	33
20	CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions. <i>Molecular Carcinogenesis</i> , 2017, 56, 2245-2257.	2.7	26
21	Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2017, 135, 217-227.	2.9	16
22	Fluorescence in situ hybridization is superior for monitoring Epstein Barr viral load in infectious mononucleosis patients. <i>BMC Infectious Diseases</i> , 2017, 17, 323.	2.9	11
23	Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress. <i>Oncotarget</i> , 2016, 7, 25478-25492.	1.8	36
24	MiR-29c regulates the expression of miR-34c and miR-449a by targeting DNA methyltransferase 3a and 3b in nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2016, 16, 218.	2.6	31
25	MiR-34b-3 and miR-449a inhibit malignant progression of nasopharyngeal carcinoma by targeting lactate dehydrogenase A. <i>Oncotarget</i> , 2016, 7, 54838-54851.	1.8	30
26	Fra-1 is upregulated in gastric cancer tissues and affects the PI3K/Akt and p53 signaling pathway in gastric cancer. <i>International Journal of Oncology</i> , 2015, 47, 1725-1734.	3.3	40
27	CD90 is upregulated in gastric cancer tissues and inhibits gastric cancer cell apoptosis by modulating the expression level of SPARC protein. <i>Oncology Reports</i> , 2015, 34, 2497-2506.	2.6	19
28	HIF-1A and C/EBPs transcriptionally regulate adipogenic differentiation of bone marrow-derived MSCs in hypoxia. <i>Stem Cell Research and Therapy</i> , 2015, 6, 21.	5.5	55
29	Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. <i>Oncotarget</i> , 2015, 6, 3147-3164.	1.8	65
30	miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. <i>Oncology Reports</i> , 2014, 32, 957-964.	2.6	52
31	miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. <i>Carcinogenesis</i> , 2013, 34, 415-425.	2.8	108
32	Tumor-Conditioned Mesenchymal Stem Cells Display Hematopoietic Differentiation and Diminished Influx of Ca <sup>2+</sup> . <i>Stem Cells and Development</i> , 2012, 21, 1418-1428.	2.1	16
33	An in silicoanalysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. <i>BMC Medical Genomics</i> , 2012, 5, 3.	1.5	88
34	Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. <i>Cytherapy</i> , 2009, 11, 516-526.	0.7	59